---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-001799"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T03:21:30.716201+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Barinthus Bio reports $142M cash, extends runway to Q4 2025, details 2024 milestones

## Summary
- Preliminary cash and equivalents: $142M as of Dec 31, 2023; ~38.6M ordinary shares outstanding.
- Cash runway extended from Q2 to Q4 2025 by deferring VTP-1100 IND in HPV cancer and phasing manufacturing.
- H1 2024: initiate Phase 1 trial of VTP-1000 in Celiac Disease; final Phase 1b/2 VTP-200 (HPV) data.
- H1 2024: interim data from HBV003 (Phase 2b VTP-300 dosing) and AB-729-202 (VTP-300 + imdusiran) trials.
- H2 2024: interim data from third arm of AB-729-202 adding nivolumab to VTP-300 and imdusiran.

## SEC filing metadata
- accession: 0001104659-24-001799
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000110465924001799/0001104659-24-001799-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000110465924001799/tm242118d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-001799
- JSON: https://secwatch.observer/filing/0001104659-24-001799.json
- Plain text: https://secwatch.observer/filing/0001104659-24-001799.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.